Latest & greatest articles for cardiovascular disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cardiovascular disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cardiovascular disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cardiovascular disease

141. Application of a Lifestyle-Based Tool to Estimate Premature Cardiovascular Disease Events in Young Adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study

Application of a Lifestyle-Based Tool to Estimate Premature Cardiovascular Disease Events in Young Adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study 28715555 2017 07 17 2017 07 17 2168-6114 2017 Jul 17 JAMA internal medicine JAMA Intern Med Application of a Lifestyle-Based Tool to Estimate Premature Cardiovascular Disease Events in Young Adults: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. 10.1001/jamainternmed.2017.2922 Few tools exist (...) for assessing the risk for early atherosclerotic cardiovascular disease (ASCVD) events in young adults. To assess the performance of the Healthy Heart Score (HHS), a lifestyle-based tool that estimates ASCVD events in older adults, for ASCVD events occurring before 55 years of age. This prospective cohort study included 4893 US adults aged 18 to 30 years from the Coronary Artery Risk Development in Young Adults (CARDIA) study. Participants underwent measurement of lifestyle factors from March 25, 1985

Full Text available with Trip Pro

2017 EvidenceUpdates

142. Omega-3 Fatty Acids and Cardiovascular Disease: Current State of the Evidence

Omega-3 Fatty Acids and Cardiovascular Disease: Current State of the Evidence Omega-3 Fatty Acids and Cardiovascular Disease: Current State of the Evidence Focus of This Summary This is a summary of a systematic review that evaluated the recent evidence regarding the effects of omega-3 fatty acids (FAs), primarily from marine oil supplements, on clinical and selected intermediate cardiovascular (CV) outcomes (i.e., blood pressure, lipid concentrations) and the association of omega-3 FA dietary (...) clinical recommendations or guidelines. Heart and Blood Vessel Conditions Heart Disease Background The first observation of a link between fish consumption and cardiovascular (CV) health was made in the late 1970s in a Greenland Eskimo population. This population exhibited a comparatively low rate of CV mortality and consumed a greater than average amount of fish. Since this original observation, there have been hundreds of studies conducted to evaluate the effect of omega-3 fatty acids (FAs

2017 Effective Health Care Program (AHRQ)

143. Supplemental Project To Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease

Supplemental Project To Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease Methods Research Report Supplemental Project To Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease Methods Research Report Supplemental Project To Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health (...) Project to Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease. Methods Research Report. (Prepared by the Brown University Evidence-based Practice Center under Contract No. 290-2015-00002-I; 290-32004- T). AHRQ Publication No. 17-EHC019-EF. Rockville, MD: Agency for Healthcare Research and Quality. June 2017. www.effectivehealthcare.ahrq.gov/reports/final.cfm. DOI: https:// doi.org/10.23970/AHRQEPCMETH3. ii Preface The Agency for Healthcare Research

2017 Effective Health Care Program (AHRQ)

144. Status of antioxidant and homocysteine-lowering vitamins related to cardiovascular diseases in hemodialysis patients (PubMed)

Status of antioxidant and homocysteine-lowering vitamins related to cardiovascular diseases in hemodialysis patients 28894552 2018 11 13 2008-5842 9 7 2017 Jul Electronic physician Electron Physician Status of antioxidant and homocysteine-lowering vitamins related to cardiovascular diseases in hemodialysis patients. 4895-4898 10.19082/4895 Cardiovascular disease is the major cause of mortality in hemodialysis patients. Oxidative stress and hyperhomocysteinemia may contribute to an increased (...) risk of CVD. Therefore, we assessed the status of antioxidant and homocysteine-lowering vitamins related to cardiovascular disease in hemodialysis patients at Vasei hospital in Sabzevar. In this cross-sectional study, we enrolled 75 hemodialysis patients by using census method at Vasei Hospital in Sabzevar (Iran) in 2014. After measuring height and body weight, food intake was assessed by a 24-hour dietary recall questionnaire for at least two days (a non-dialysis and dialysis day), and food

Full Text available with Trip Pro

2017 Electronic physician

145. Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. (PubMed)

Cardiovascular Disease Among Transgender Adults Receiving Hormone Therapy: A Narrative Review. Recent reports estimate that 0.6% of adults in the United States, or approximately 1.4 million persons, identify as transgender. Despite gains in rights and media attention, the reality is that transgender persons experience health disparities, and a dearth of research and evidence-based guidelines remains regarding their specific health needs. The lack of research to characterize cardiovascular (...) disease (CVD) and CVD risk factors in transgender populations receiving cross-sex hormone therapy (CSHT) limits appropriate primary and specialty care. As with hormone therapy in cisgender persons (that is, those whose sex assigned at birth aligns with their gender identity), existing research in transgender populations suggests that CVD risk factors are altered by CSHT. Currently, systemic hormone replacement for cisgender adults requires a nuanced discussion based on baseline risk factors and age

2017 Annals of Internal Medicine

146. Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement. (PubMed)

Behavioral Counseling to Promote a Healthful Diet and Physical Activity for Cardiovascular Disease Prevention in Adults Without Cardiovascular Risk Factors: US Preventive Services Task Force Recommendation Statement. Importance: Adults who adhere to national guidelines for a healthful diet and physical activity have lower rates of cardiovascular morbidity and mortality than those who do not. All persons, regardless of their risk status for cardiovascular disease (CVD), can gain health benefits (...) from healthy eating behaviors and appropriate physical activity. Objective: To update the 2012 US Preventive Services Task Force (USPSTF) recommendation on behavioral counseling to promote a healthful diet and physical activity for cardiovascular disease prevention among adults without obesity who do not have cardiovascular risk factors (hypertension, dyslipidemia, abnormal blood glucose levels, or diabetes). Evidence Review: The USPSTF reviewed the evidence on whether primary care-relevant

Full Text available with Trip Pro

2017 JAMA

147. Awareness of cardiovascular disease, its risk factors, and its association with attendance at outpatient clinics in acute coronary syndrome patients (PubMed)

Awareness of cardiovascular disease, its risk factors, and its association with attendance at outpatient clinics in acute coronary syndrome patients 28951837 2018 11 13 2213-4220 6 3 2017 Sep Integrative medicine research Integr Med Res Awareness of cardiovascular disease, its risk factors, and its association with attendance at outpatient clinics in acute coronary syndrome patients. 240-244 10.1016/j.imr.2017.06.003 The objective was to assess patients' awareness of cardiovascular disease, its (...) of arterial hypertension slightly increased with increasing attendance ( p > 0.05), whereas awareness of dyslipidemia increased dramatically ( p < 0.01). Our study showed significant differences between medical history data received from patients and data obtained from objective examination for several cardiovascular disease risk factors in patients with ACS. Awareness of dyslipidemia was very low. It increased dramatically with increasing attendance. At the same time, there was only a slight increase

Full Text available with Trip Pro

2017 Integrative medicine research

148. Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981-2010. (PubMed)

Benchmarking life expectancy and cancer mortality: global comparison with cardiovascular disease 1981-2010. Objective To quantify the impact of cancer (all cancers combined and major sites) compared with cardiovascular disease (CVD) on longevity worldwide during 1981-2010. Design Retrospective demographic analysis using aggregated data. Setting National civil registration systems in member states of the World Health Organization. Participants 52 populations with moderate to high quality data (...) on cause specific mortality. Main outcome measures Disease specific contributions to changes in life expectancy in ages 40-84 (LE 40-84 ) over time in populations grouped by two levels of Human Development Index (HDI) values. Results Declining CVD mortality rates during 1981-2010 contributed to, on average, over half of the gains in LE 40-84 ; the corresponding gains were 2.3 (men) and 1.7 (women) years, and 0.5 (men) and 0.8 (women) years in very high and medium and high HDI populations, respectively

Full Text available with Trip Pro

2017 BMJ

149. Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. (PubMed)

Clonal Hematopoiesis and Risk of Atherosclerotic Cardiovascular Disease. Background Clonal hematopoiesis of indeterminate potential (CHIP), which is defined as the presence of an expanded somatic blood-cell clone in persons without other hematologic abnormalities, is common among older persons and is associated with an increased risk of hematologic cancer. We previously found preliminary evidence for an association between CHIP and atherosclerotic cardiovascular disease, but the nature (...) of this association was unclear. Methods We used whole-exome sequencing to detect the presence of CHIP in peripheral-blood cells and associated such presence with coronary heart disease using samples from four case-control studies that together enrolled 4726 participants with coronary heart disease and 3529 controls. To assess causality, we perturbed the function of Tet2, the second most commonly mutated gene linked to clonal hematopoiesis, in the hematopoietic cells of atherosclerosis-prone mice. Results

Full Text available with Trip Pro

2017 NEJM

150. Urinary Stone Disease and Cardiovascular Disease Risk in a Rural Chinese Population (PubMed)

Urinary Stone Disease and Cardiovascular Disease Risk in a Rural Chinese Population 29270513 2018 11 13 2468-0249 2 6 2017 Nov Kidney international reports Kidney Int Rep Urinary Stone Disease and Cardiovascular Disease Risk in a Rural Chinese Population. 1042-1049 10.1016/j.ekir.2017.06.001 Urinary stone disease (USD) is associated with cardiovascular disease (CVD) in Western populations. However, the prevalence and relationship between USD and CVD risk have not been fully examined (...) Hospital, Beijing, China. Thadhani Ravi R Department of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA. Li Xuemei X Department of Nephrology, Peking Union Medical College Hospital, Beijing, China. eng K23 DK106479 DK NIDDK NIH HHS United States Journal Article 2017 06 08 United States Kidney Int Rep 101684752 2468-0249 arterial stiffness cardiovascular risk chronic kidney disease hypertension peripheral arterial disease urinary stone disease 2017 03 07 2017 05 14 2017 06 01 2017

Full Text available with Trip Pro

2017 Kidney international reports

151. Out-of-pocket expenditures for prevention and treatment of cardiovascular disease in general and specialised cardiac hospitals in Addis Ababa, Ethiopia: a cross-sectional cohort study (PubMed)

Out-of-pocket expenditures for prevention and treatment of cardiovascular disease in general and specialised cardiac hospitals in Addis Ababa, Ethiopia: a cross-sectional cohort study 29242752 2018 11 13 2059-7908 2 2 2017 BMJ global health BMJ Glob Health Out-of-pocket expenditures for prevention and treatment of cardiovascular disease in general and specialised cardiac hospitals in Addis Ababa, Ethiopia: a cross-sectional cohort study. e000280 10.1136/bmjgh-2016-000280 Cardiovascular disease (...) poses a great financial risk on households in countries without universal health coverage like Ethiopia. This paper aims to estimate the magnitude and intensity of catastrophic health expenditure and factors associated with catastrophic health expenditure for prevention and treatment of cardiovascular disease in general and specialised cardiac hospitals in Addis Ababa. We conducted a cross-sectional cohort study among individuals who sought cardiovascular disease care in selected hospitals in Addis

Full Text available with Trip Pro

2017 BMJ global health

152. Supplemental Project To Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease

Supplemental Project To Assess the Transparency of Reporting Requirements: Omega-3 Fatty Acids and Cardiovascular Disease

2017 Effective Health Care Program (AHRQ)

153. Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease

Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease 28473506 2017 05 05 2017 05 05 1468-3296 2017 May 04 Thorax Thorax Cardiovascular and neuropsychiatric risks of varenicline and bupropion in smokers with chronic obstructive pulmonary disease. thoraxjnl-2017-210067 10.1136/thoraxjnl-2017-210067 Varenicline and bupropion are effective smoking cessation treatments, but there are concerns about their safety in smokers (...) with COPD. To investigate whether varenicline and bupropion are associated with serious adverse cardiovascular and neuropsychiatric events in smokers with COPD. In a retrospective cohort study, we used data from 14 350 patients with COPD included in the QResearch database, which holds data from 753 National Health Service general practices across England. We identified patients with COPD who received a prescription of nicotine replacement therapy (NRT; N=10 426; reference group), bupropion (N=350

Full Text available with Trip Pro

2017 EvidenceUpdates

154. Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study)

Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study) 28487034 2017 05 10 2017 06 12 1879-1913 120 1 2017 Jul 01 The American journal of cardiology Am. J. Cardiol. Usefulness of Multiple Biomarkers for Predicting Incident Major Adverse Cardiac Events in Patients Who Underwent Diagnostic Coronary Angiography (from (...) the Catheter Sampled Blood Archive in Cardiovascular Diseases [CASABLANCA] Study). 25-32 S0002-9149(17)30636-7 10.1016/j.amjcard.2017.03.265 We sought to develop a multiple biomarker approach for prediction of incident major adverse cardiac events (MACE; composite of cardiovascular death, myocardial infarction, and stroke) in patients referred for coronary angiography. In a 649-participant training cohort, predictors of MACE within 1 year were identified using least-angle regression; over 50 clinical

2017 EvidenceUpdates

155. Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA?

Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA? 28365576 2017 04 02 2017 06 06 0315-162X 44 6 2017 Jun The Journal of rheumatology J. Rheumatol. Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA? 732-739 10.3899/jrheum.161154 To assess trends in cardiovascular (CV) mortality in patients (...) Exp Rheumatol. 2016 Sep-Oct;34(5):813-819 27494398 J Rheumatol. 1997 Mar;24(3):445-51 9058647 Rheumatology (Oxford). 2011 Jan;50(1):6-15 20627969 Arthritis Rheum. 2008 Sep;58(9):2603-11 18759286 Arthritis Rheum. 2010 Jun;62(6):1576-82 20191579 Clin Exp Rheumatol. 2008 Sep-Oct;26(5 Suppl 51):S35-61 19026144 J Am Acad Dermatol. 2005 Feb;52(2):262-7 15692471 CARDIOVASCULAR DISEASE CORONARY HEART DISEASE MORTALITY RHEUMATOID ARTHRITIS 2017 02 17 2018 06 01 2017 4 4 6 0 2017 4 4 6 0 2017 4 3 6 0

2017 EvidenceUpdates

156. Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease (PubMed)

Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease 29044395 2018 12 11 2018 12 11 2058-1742 3 4 2017 10 01 European heart journal. Quality of care & clinical outcomes Eur Heart J Qual Care Clin Outcomes Modelling total coronary heart disease burden and long-term benefit of cholesterol lowering in middle aged men with and without a history of cardiovascular disease. 281-288 10.1093 (...) Research Support, Non-U.S. Gov't England Eur Heart J Qual Care Clin Outcomes 101677796 2058-1742 0 Anticholesteremic Agents 0 Biomarkers 0 Cholesterol, LDL IM Eur Heart J Qual Care Clin Outcomes. 2017 Oct 1;3(4):256-257 28950360 Anticholesteremic Agents therapeutic use Biomarkers blood Cardiovascular Diseases epidemiology Cholesterol, LDL blood Coronary Disease blood drug therapy economics Cost of Illness Follow-Up Studies Humans Incidence Male Middle Aged Retrospective Studies Risk Factors Scotland

Full Text available with Trip Pro

2017 European heart journal. Quality of care & clinical outcomes

157. Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease (PubMed)

Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease 29063061 2018 11 13 2095-882X 3 2 2017 Jun 25 Chronic diseases and translational medicine Chronic Dis Transl Med Association between circulating oxidized low-density lipoprotein and atherosclerotic cardiovascular disease. 89-94 10.1016/j.cdtm.2017.02.008 Atherosclerosis is a chronic, progressive disease which eventually leads to coronary heart disease (CHD), ischemic stroke and other (...) atherosclerotic cardiovascular disease (ASCVD). Numerous studies have demonstrated an atherogenic role of oxidized low-density lipoprotein (ox-LDL) in the progression of ASCVD. This article briefly reviews the atherogenic mechanism of ox-LDL, the methods of measuring ox-LDL in the circulation, effect of medical therapy and life-style modification on ox-LDL level, and the association between circulating ox-LDL and atherosclerosis, including clinical ASCVD events and subclinical atherosclerosis

Full Text available with Trip Pro

2017 Chronic diseases and translational medicine

158. Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. (PubMed)

Genetic and Pharmacologic Inactivation of ANGPTL3 and Cardiovascular Disease. Background Loss-of-function variants in the angiopoietin-like 3 gene (ANGPTL3) have been associated with decreased plasma levels of triglycerides, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. It is not known whether such variants or therapeutic antagonism of ANGPTL3 are associated with a reduced risk of atherosclerotic cardiovascular disease. Methods We sequenced the exons (...) with decreased levels of all three major lipid fractions and decreased odds of atherosclerotic cardiovascular disease. (Funded by Regeneron Pharmaceuticals and others; ClinicalTrials.gov number, NCT01749878 .).

Full Text available with Trip Pro

2017 NEJM

159. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. (PubMed)

Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. Objectives To develop and validate updated QRISK3 prediction algorithms to estimate the 10 year risk of cardiovascular disease in women and men accounting for potential new risk factors. Design Prospective open cohort study. Setting General practices in England providing data for the QResearch database. Participants 1309 QResearch general practices (...) in England: 981 practices were used to develop the scores and a separate set of 328 practices were used to validate the scores. 7.89 million patients aged 25-84 years were in the derivation cohort and 2.67 million patients in the validation cohort. Patients were free of cardiovascular disease and not prescribed statins at baseline. Methods Cox proportional hazards models in the derivation cohort to derive separate risk equations in men and women for evaluation at 10 years. Risk factors considered

Full Text available with Trip Pro

2017 BMJ

160. Model for end‐stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease (PubMed)

Model for end‐stage liver disease Na Score predicts incident major cardiovascular events in patients with nonalcoholic fatty liver disease 29085919 2018 11 13 2471-254X 1 5 2017 Jul Hepatology communications Hepatol Commun MELD-Na score predicts incident major cardiovascular events, in patients with nonalcoholic fatty liver disease (NAFLD). 429-438 10.1002/hep4.1051 Cardiovascular disease (CVD) is the leading cause of mortality among adults with nonalcoholic fatty liver disease (NAFLD (...) for Assessment Technology and Continuous Health, Massachusetts General Hospital, Boston, MA, USA. Corey Kathleen E KE Liver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital. Harvard Medical School, Boston, MA. eng K23 DK099422 DK NIDDK NIH HHS United States T32 DK007191 DK NIDDK NIH HHS United States Journal Article 2017 05 22 United States Hepatol Commun 101695860 2471-254X NAFLD biomarker cardiovascular disease fibrosis inflammation prevention risk prediction

Full Text available with Trip Pro

2017 Hepatology communications